Molecularly targeted therapies in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is an incurable blood cancer characterized by treatment resistance.
• Despite treatment advances, relapse and refractoriness remain significant challenges for MM patients.
• Novel therapeutic agents are crucial for managing relapsed/refractory MM.

Purpose of the Study:

• To review molecular targeted therapies for relapsed/refractory multiple myeloma (MM).
• To focus on cell signaling pathways and tumor microenvironment strategies.
• To highlight agents beyond immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.

Main Methods:

• Literature review of contemporary research on MM targeted therapies.
• Focus on molecular mechanisms including cell signaling pathways (e.g., HDAC, PI3K/AKT/mTOR, MAPK, Hsp90, Wnt, Notch, Hedgehog, cell cycle).
• Examination of strategies targeting the tumor microenvironment (e.g., hypoxia, angiogenesis, integrins, CD44, CXCR4, selectins).

Main Results:

• Several novel molecular targeted therapies are under development for relapsed/refractory MM.
• Targeting cell signaling pathways shows promise in overcoming resistance mechanisms.
• Strategies modulating the tumor microenvironment offer new therapeutic avenues.

Conclusions:

• Molecular targeted therapies, including cell signaling and tumor microenvironment strategies, are advancing MM treatment.
• These novel agents improve outcomes for patients with relapsed/refractory MM.
• Continued development of innovative therapeutic agents is essential for improving MM patient survival.